Multiple Sclerosis & Immune Disorders

Filter Your Results

 

News

 

ECTRIMS: Genentech Data Signals Emphasis on Multiple Sclerosis Disease Progression, Disability

Friday, October 27, 2017—Data presented by Genentech at the 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) -- Americas Committee for Treatment and Research i…

ECTRIMS: Alkermes Demontrates Safety and GI Tolerability of Investigational Oral Agent for Relapsing MS

Friday, October 27, 2017—Alkermes presented safety and gastrointestinal (GI) tolerability data from EVOLVE-MS-1, an ongoing open-label, two-year phase 3 safety study for ALKS 8700, a novel, oral monom…

ECTRIMS: EMD Serono Highlights Risk-Benefit Profile of Cladribine Tablets for Relapsing MS

Friday, October 27, 2017—Data from a post-hoc analysis presented by Merck at the 7th Joint ECTRIMS-ACTRIMS Meeting in Paris show that investigational Cladribine Tablets significantly increases the pro…

ECTRIMS: First-in-Class Monoclonal Antibody Shows Promise in Phase 2 Data

Friday, October 27, 2017—Results from the Phase 2 SYNERGY trial suggest that the investigational opicinumab (Biogen) could have an increased clinical effect in patients with relapsing multiple scleros…

Corrona Partners with National MS Society on Registry to Assess Safety and Efficacy of Therapies

Friday, October 20, 2017—Corrona, LLC and the National Multiple Sclerosis Society will collaborate on the launch of the Corrona Multiple Sclerosis (MS) Registry to study the comparative safety and eff…

FDA Greenlights Two Generic Glatiramer Acetate Formulations for Relapsing MS

Wednesday, October 04, 2017—The FDA approved Mylan’s generic versions of glatiramer acetate, including a three-times weekly 40mg/mL formulation of glatiramer acetate and a once-…

Vitamin D Levels Tied to Risk of MS

Thursday, September 14, 2017—Examining vitamin D levels in the blood may help predict whether a person is at risk of developing multiple sclerosis (MS), according to a large new study published Neurology&…

Project ALS and Amylyx Team Up to Test Phase 2 Compound

Thursday, September 07, 2017—Project ALS and Amylyx Pharmaceuticals are collaborating to undertake pre-clinical studies to advance the understanding of Amylyx's oral compound AMX0035 for the treatment…

 
 

Contact Info

For advertising rates and opportunities:
Wendy Terry
Publisher
217-652-3859
wterry@bmctoday.com

About Practical Neurology

Launched in January 2002, Practical Neurology strives to enhance quality of care and improve the daily operation of neurology practices. Each month, our experts explain the real-world significance of recent advances in neurologic science and offer step-by-step advice on how to overcome the clinical and business challenges neurologists face. Our straightforward, how-to articles give neurologists tools they can put into practice right away.

 
  • BRYN MAWR COMMUNICATIONS III, LLC